Anti-VEGF intravitreal injections in the era of COVID-19: responding to different levels of epidemic pressure

Creative Commons License

Korobelnik J., Loewenstein A., Eldem B., Joussen A. M., Koh A., Lambrou G. N., ...Daha Fazla

GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY, cilt.259, sa.3, ss.567-574, 2021 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Derleme
  • Cilt numarası: 259 Sayı: 3
  • Basım Tarihi: 2021
  • Doi Numarası: 10.1007/s00417-021-05097-0
  • Dergi Adı: GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, BIOSIS, CAB Abstracts, EMBASE, MEDLINE, Veterinary Science Database
  • Sayfa Sayıları: ss.567-574
  • Anahtar Kelimeler: Retinal disease, Ophthalmology, COVID-19, Coronavirus, Recommendations, Vision Academy, RANIBIZUMAB
  • Hacettepe Üniversitesi Adresli: Evet

Özet

Purpose Following the first wave of the COVID-19 pandemic in early 2020, the easing of strict measures to reduce its spread has led to a resurgence of cases in many countries at both the national and local level. This article addresses how guidance for ophthalmologists on managing patients with retinal disease receiving intravitreal injections of anti-vascular endothelial growth factor (VEGF) during the pandemic should be adapted to the local epidemic pressure, with more or less stringent measures implemented according to the ebb and flow of the pandemic.